New inhaled powder for lung blood pressure condition tested in 80 patients

NCT ID NCT06129240

Recruiting now Disease control Sponsor: Liquidia Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the safety of an inhaled dry powder form of treprostinil (LIQ861) for people with pulmonary hypertension (high blood pressure in the lungs) due to lung disease. About 80 adults will take the drug using a special inhaler, and researchers will monitor for side effects. The goal is to see if this new way of delivering the medicine is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: treprostinil inhalation powder (LIQ861)
What this could lead to: If it works, this could provide a more convenient, dry-powder inhaled option to help control pulmonary hypertension.
What could go wrong: This is an early safety study with only 80 participants, so it may not prove effectiveness. Side effects from treprostinil can include headache, nausea, and jaw pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary arterial hypertension pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE PULMONARY HYPERTENSION

Contacts and locations

Locations

Advent Health
RECRUITING

Orlando, Florida, 32803, United States
Arizona Pulmonary Specialists
RECRUITING

Phoenix, Arizona, 85012, United States
Hartford Hospital
WITHDRAWN

Hartford, Connecticut, 06102, United States
Houston Methodist
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
NYU Langone Medical Center
ACTIVE_NOT_RECRUITING

New York, New York, 10016, United States
National Jewish Health
RECRUITING

Denver, Colorado, 80206, United States
Norton Pulmonary Specialists
WITHDRAWN

Louisville, Kentucky, 40241, United States
Summit Health
RECRUITING

Bend, Oregon, 97701, United States
Tampa General Hospital Center of Research Excellence
RECRUITING

Tampa, Florida, 33606, United States
The Medical Research Group, Inc.
RECRUITING

Fresno, California, 93720, United States
Tufts Medical Center
WITHDRAWN

Boston, Massachusetts, 02111, United States
UC Davis
ACTIVE_NOT_RECRUITING

Sacremento, California, 95817, United States
UCLA Westwood
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90095, United States
UCSF
ACTIVE_NOT_RECRUITING

San Francisco, California, 94143, United States
University of California San Diego
WITHDRAWN

La Jolla, California, 92093, United States
University of Cincinnati Health
ACTIVE_NOT_RECRUITING

Cincinnati, Ohio, 45219, United States
University of Michigan
ACTIVE_NOT_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Minnesota
ACTIVE_NOT_RECRUITING

Minneapolis, Minnesota, 55455, United States
University of North Carolina at Chapel Hill
WITHDRAWN

Chapel Hill, North Carolina, 27514, United States
University of Rochester
ACTIVE_NOT_RECRUITING

Rochester, New York, 14627, United States
University of Utah
ACTIVE_NOT_RECRUITING

Salt Lake City, Utah, 84112, United States
Vincent Medical Group
RECRUITING

Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.